DESTINY-Gastric03 Trial
Phase 2
413
about 7 years
18–130
10 sites in CA, KS, MA +6
What this study is about
This trial is testing whether T-DXd, alone or in combination with other treatments like chemotherapy and/or immunotherapy, can safely treat advanced gastric cancer. The goal is to see if these combinations are safe, well-tolerated, and effective at fighting the cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Durvalumab
- 2.Receive Pembrolizumab
- 3.Receive Rilvegostomig
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
capecitabine, cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), durvalumab, fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), oxaliplatin, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), trastuzumab (Monoclonal antibody; targets HER2 protein on cancer cells), trastuzumab deruxtecan
oral (Oral Tablet), injection, intravenous, infusion, oral (Oral Capsule), injection (Injection)
Primary: Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0, Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)
Secondary: Comparison of DCR, Comparison of DoR, Comparison of ORR, Comparison of OS, Comparison of PFS, Disease Control Rate (DCR), Duration of Response (DoR), Overall survival (OS)